Alkermes escalates bidding war; US biotech risks ‘falling behind’ China

A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.

By BioPharma Dive staff • Nov. 19, 2025

RNAi biotech Arrowhead wins first FDA approval

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a commercial-stage company and sets up a turf war with Ionis Pharmaceuticals.

By Delilah Alvarado • Updated Nov. 18, 2025

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Zymeworks to change course, pursue ‘royalty-driven’ biotech model

On the heels of a data readout suggesting one of its cancer drugs could become a future blockbuster, Zymeworks is adopting a new strategy its CEO says will create “more consistent value for shareholders.”

By Gwendolyn Wu • Nov. 18, 2025

J&J adds to pharma’s M&A spree with $3B buyout of startup Halda

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s shown promise in early-stage testing. 

By Jonathan Gardner • Nov. 17, 2025

FDA limits Elevidys use; Nxera to lay off staff

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

By Ben Fidler • Nov. 17, 2025

Solve lines up $120M to push ADCs into further testing

The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of the issues limiting the potential of earlier ADCs. 

By Delilah Alvarado • Nov. 17, 2025

A ‘DNA damage repair’ drugmaker raises $115M for cancer treatments

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its Series D round will help advance ongoing mid-stage studies.

By Gwendolyn Wu • Nov. 17, 2025

Sofinnova Partners raises another $750M to back biotech, medtech startups

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on rounds. 

By Gwendolyn Wu • Nov. 16, 2025

Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

By BioPharma Dive staff • Nov. 14, 2025

Medicxi closes sixth fund to back ‘asset-centric’ startups

The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of recent buyout deals involving portfolio companies like Merus and Vicebio.

By Gwendolyn Wu • Nov. 14, 2025

Day One snaps up ADC maker Mersana in backloaded buyout deal

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only materialize if its main cancer drug hits a variety of milestones.

By Jonathan Gardner • Nov. 13, 2025

Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data

Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket. 

By Ben Fidler • Nov. 12, 2025

Neurocrine chalks up a depression drug failure

Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program were "near-zero."

By Jacob Bell • Nov. 10, 2025

Lilly picks up an eye gene therapy in deal with MeiraGTx

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment for an ultra-rare form of childhood blindness.

By Gwendolyn Wu • Nov. 10, 2025

Patient dies in Intellia trial; FDA awards 6 more ‘national priority’ vouchers

The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

By BioPharma Dive staff • Nov. 7, 2025

AstraZeneca exercises option to buy an obesity startup

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

By Gwendolyn Wu • Nov. 6, 2025

Moderna leans on cost cuts, pipeline as vaccine sales dip

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to break even financially in 2028 with the help of more disciplined spending. 

By Delilah Alvarado • Nov. 6, 2025

Evommune nabs $150M in IPO amid federal shutdown

The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities law to price an offering during the shutdown. 

By Gwendolyn Wu • Nov. 5, 2025

Soleno slumps despite sales uptick; Madrigal’s MASH drug continues ascent

Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer medicine at the center of a $1.9 billion buyout fell short in a key trial. 

By BioPharma Dive staff • Nov. 5, 2025

Braveheart secures $185M to advance challenger to Bristol Myers heart drug

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.

By Ben Fidler • Nov. 5, 2025

Vertex’s new pain, blood disorder drugs miss Wall Street expectations

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.

By Jacob Bell • Nov. 4, 2025

Sarepta Duchenne drugs come up short in confirmatory test

Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and that the evidence accrued to date makes a strong case for full approval.

By Ben Fidler • Nov. 4, 2025

Neok Bio launches with $75M to make dual-targeting ADCs

The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by simultaneously homing in on “unique pairs” of cancer targets. 

By Delilah Alvarado • Nov. 4, 2025

UniQure dives after FDA’s ‘very surprising’ reversal on Huntington’s gene therapy

The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as it's been in years, some analysts said.

By Jacob Bell • Nov. 3, 2025

Caribou results suggest renewed promise for ‘off-the-shelf’ cancer cell therapy

While early, the data support Caribou’s plan to boost its therapies’ effectiveness by using donor cells that are carefully matched to a patient’s immune system. 

By Jonathan Gardner • Nov. 3, 2025